Bruyère Research Institute

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease6 trials
• Frontotemporal dementia2 trials
• Lewy body dementia1 trial
• Mild cognitive impairment1 trial
• Parkinson disease1 trial

Phase

• Phase 24 trials
• Phase 31 trial

Status

• Completed4 trials
• Active, not recruiting2 trials

Lead sponsor

• Eli Lilly and Company3 trials
• Alector Inc.1 trial
• IntelGenx Corp.1 trial
• McGill University1 trial

Running trials

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Comprehensive Assessment of Neurodegeneration and Dementia

  NCT03402919· McGill University· Source

  Contact: Howard Chertkow, MD

Closed trials

• Completed

  A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

  NCT05063539· Phase 2· Eli Lilly and Company· Source

• Completed

  A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

  NCT04592874· Phase 2· Alector Inc.· Source

• Completed

  A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

  NCT04640077· Phase 2· Eli Lilly and Company· Source

• Completed

  Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

  NCT03402503· Phase 2· IntelGenx Corp.· Source